# Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

> **NCT02630251** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Cancer
- Neoplasms

## Interventions

- **DRUG:** GSK2820151

## Key facts

- **NCT ID:** NCT02630251
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-25
- **Primary completion:** 2018-12-13
- **Final completion:** 2018-12-13
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630251, "Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02630251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*